On June 3, 2026 Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a leading provider of AI-based image analyses and central imaging services for oncology clinical trials in the biopharmaceutical industry, reported the success of its upsized capital increase without shareholders’ preferential subscription rights, by way of an issuance of new ordinary shares (the "New Shares"). The New Shares were offered in the framework of (i) a public offering in France and a global placement to certain qualified investors for an amount of €40 million and (ii) an offering reserved to Katarina Martinson AB, Venture S.a.r.l, and Nordica Life (Bermuda) Ltd (the "Guarantors") for an amount of €10 million
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Offering (as such term is defined below), launched on May 27, 2026, amounted to a total gross proceed of €50 million, including the issuance premium. The initial capital increase of €40 million capital increase was multiple times oversubscribed, demonstrating strong market support. The Offering attracted strong demand from both existing and new institutional investors across Europe, the United States and the United Kingdom, alongside significant participation from retail investors. Given the level of oversubscription recorded, the Reserved Offering to the Guarantors for a maximum amount of € 10 million was fully implemented, bringing the total amount of the transaction to € 50 million.
"On behalf of Median Technologies, I would like to thank all investors—both institutional and retail—for their participation in this capital increase and their confidence in our vision and strategy. This transaction has enabled us to further diversify and strengthen our shareholder base with leading institutional investors from Europe, the United States, and the United Kingdom. We are also grateful for the continued support of Lion Point Capital, which joined Median in 2025, as well as the Guarantors, whose commitment contributed significantly to the success of this transaction," said Fredrik Brag, CEO and Founder of Median Technologies.
"With this financing, Median Technologies believes that it is well positioned to execute its strategic roadmap. The proceeds provide funding visibility into the first half of 2028 and could extend through mid-2029 upon the full exercise of the warrants issued in 2025 and still outstanding," Fredrik Brag added.
"Our priorities are clear: the commercial deployment of eyonis LCS in the United States, its commercial launch in Europe following the expected CE marking in the coming weeks, and the expansion of our eyonis platform into additional cancer indications. We believe early cancer diagnosis is a significant opportunity to improve patient outcomes while helping healthcare systems address the growing burden of cancer. This financing provides the resources to accelerate that mission and create long-term value for patients, healthcare providers, and shareholders alike," concluded Fredrik Brag.
Main Terms of the Offering
Pursuant to the 3rd and 5th resolutions of the general meeting of the shareholders held on October 31, 2025 (the "General Meeting") and the sub-delegation of powers from the Company’s Board of Directors (Conseil d’Administration) held on May 26, 2026, the Chief Executive Officer of the Company decided, on June 3, 2026, to issue 10,000,000 New Shares, excluding the Commission (as such term is defined below) at a price of €5.00 per New Share (i.e. €0.05 nominal value and €4.95 issue premium), representing approximately 31% of the Company’s existing share capital on a non-diluted basis, and corresponding to a capital increase of a total amount of €50,000,000, including issue premium. The price per New Share represents a discount of (i) 2.85% to the volume-weighted average prices (VWAP) of the Company’s shares recorded during the 20 trading sessions preceding May 26, 2026 (inclusive) and (ii) 11.3% to the closing price as of May, 26, 2026.
The New Shares issued in connection with the Offering comprised:
a global offering including (a) a public offering in France, mainly aimed at retail investors (the "Public Offering") and (b) an international offering to qualified investors in certain countries, including (a) in the United States of America, by way of a private placement by the Company to a limited number of "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act of 1933, as amended (the "Securities Act"), in reliance on an exemption from the registration requirements of Section 4(a)(2) of the Securities Act, and (b) outside the United States in offshore transactions in accordance with Regulation S under the Securities Act (the "Global Placement", together with the Public Offering, "Global Offering"); and
a share capital increase without shareholders’ preferential subscription rights reserved for a category of persons, for the benefit of Guarantors, in accordance with Article L.225-138 of the French Commercial Code (the "Reserved Offering", together with the "Global Offering", the "Offering",).
As part of the Public Offering: 331,790 New Shares were allocated, representing 3.3 % of the Offering;
In the Global Placement: 7,668,210 New Shares were allocated, representing 76,7 % of the Offering including 4,000,000 New Shares subscribed for and allocated to the Guarantors; and
In the Reserved Offering: 2,000,000 New Shares subscribed for and allocated to the Guarantors, representing 20% of the Offering.
In accordance with the subscription commitments granted to the Company, the Guarantors subscribed in the Global Offering for a total amount of €20,000,000 in the following proportions:
New Shares
Subscribed amount (€)
% of the Global Offering
Katarina Martinson AB
2,666,667
13,333,333
33.3 %
Venture S.a.r.l
933,333
4,666,667
11.7 %
Nordica Life (Bermuda) Ltd
400,000
2,000,000
5.0 %
TOTAL
4,000,000
20,000,000
50 %
In connection with the Reserved Offering, the Guarantors also subscribed, in accordance with the underwriting commitments granted to the Company, for a total amount of €10,000,000 in the following proportions:
New Shares
Subscribed amount (€)
% of the Global Offering
Katarina Martinson AB
1,333,333
6,666,667
16.7 %
Venture S.a.r.l
466,667
2,333,333
5.8 %
Nordica Life (Bermuda) Ltd
200,000
1,000,000
2.5 %
TOTAL
2,000,000
10,000,000
25 %
In consideration for their subscription and underwriting commitments, each Guarantor is in any event entitled to the payment of a fee equal to 8% of the aggregate amount of its subscription and underwriting commitments, i.e. a total aggregate amount of €2,400,000 for the Guarantors, payable by way of set-off of a certain and payable receivable in new shares on the settlement-delivery date of the Offering, representing 480,000 new ordinary shares (the "Commission").
Intended use of the Offering’s net proceeds
The net proceeds from the Offering will be used:
To accelerate commercialization of eyonis LCS in the U.S. and launch in target European countries after CE marking achievement,
To develop eyonis for incremental cancer indications,
For Company’s working capital and general corporate purposes.
The Offering will extend Company’s cash runway until first half-year 2028.
In case of the full exercise of the 12 million warrants issued in July 2025 that are currently outstanding, with an expiration date in January 2028 at an exercise price of €2.39 per share (remaining exercise value of €44.3 million), the cash runway of the Company would be extended to mid-2029.
Settlement of the New Shares
Settlement of the New Shares and their admission to trading on the multilateral trading facility of Euronext Growth Paris are expected to take place on June 5, 2026. The New Shares will be of the same class as, and fungible with, the existing ordinary shares, will carry all rights attached to the existing shares and will be admitted to trading on Euronext Growth Paris under the same ISIN code: FR0011049824 – ALMDT.
Impact of the Offering on the Company’s shareholding structure and shareholders’ equity
Before the Offering, and based on the information made available to the Company, the share capital and number and percentage of voting rights were allocated as follows:
non diluted basis
diluted basis(1)
Number of shares / voting rights
% of share capital and voting rights
Number of shares / voting rights
% of share capital and voting rights
Anne Helen & Fredrik Lungström
5,215,396
13.7 %
11,540,692
17.77 %
Celestial Successor Fund, LP
2,553,312
6.7 %
6,577,343
10.13 %
Matignon Finance
1,625,099
4.3 %
2,586,542
3.98 %
Furui Medical Science Company
1,507,692
3.9 %
1,507,962
2.32 %
Lion Point L P
1,506,024
3.9 %
3,765,060
5.80 %
Canon Inc
961,825
2.5 %
961,825
1.48 %
Free float
24,833,039
65.0 %
38,017,120
58. 53 %
Total
38,202,387
100.00%
64,956,544
100.0%
(1) After acquisition of the free shares granted by the Company and exercise of the stock options and share warrants issued by the Company as of 31 December 2025, corresponding to 26,754,157 shares of the Company.
After the Offering, and based on the information made available to the Company, the share capital and number and percentage of voting rights is allocated as follows:
non diluted basis
diluted basis(1)
Number of shares / voting rights
% of share capital and voting rights
Number of shares / voting rights
% of share capital and voting rights
Anne Helen & Fredrik Lungström
5,215,396
10.7%
11,540,692
15.30%
Celestial Successor fund LP
2,553,312
5.2%
6,577,343
8.72%
Matignon Finance
1,625,099
3.3%
2,586,542
3.43%
Furui Medical Science Company
1,507,692
3.1%
1,507,962
2.00%
Lion Point L P
1,506,024
3.1%
3,765,060
4.99%
Canon Inc
961,825
2.0%
961,825
1.28%
Katarina Martinson AB
4,320,000
8.9%
,4,320,000
5.73%
Venture S.a.r.l
1,512,000
3.1%
1,512,000
2.00%
Nordica Life (Bermuda) Ltd
648,000
1.3%
648,000
0.83%
Free float
28,833,039
59.2%
,42,017,120
55.70%
Total
48,682,387
100.0%
75,436,544
100.00%
(1) After acquisition of the free shares granted by the Company and exercise of the stock options and share warrants issued by the Company as of 31 December 2025, corresponding to 26,754,157 shares of the Company.
For illustrative purposes, the impact of the Offering on the ownership interest of a shareholder holding 1% of the Company’s share capital prior to the Offering and who did not subscribe to it, and on the Company’s shareholders’ equity per share, is as follows, based on the number of shares comprising the Company’s share capital as of the date of this press release, after deduction of treasury shares, and on consolidated shareholders’ equity attributable to the Group as of 31 December 2025:
Share of consolidated shareholders’ equity per share, in euros.
Ownership interest, in %.
Non-diluted basis
Diluted basis(1)
Non-diluted basis
Diluted basis(1)
Before the Offering
-0.920€
0.590€
1%
0.588%
After the Offering (excluding the Commission).
0.308€
1.315 €
0.793%
0.491%
After the Offering (including the Commission).
0.354€
1.203 €
0.785%
0.506%
(1) After acquisition of the free shares granted by the Company and exercise of the stock options and warrants issued by the Company as of 31 December 2025, corresponding to 26,754,157 shares of the Company.
Financial intermediaries
TD Cowen and Stifel Europe Securities SAS acted as Joint Global Coordinators and Joint Placement Agents for the Offering (together, the "Placement Agents"). The Offering was subject to a placement agreement between the Company and the Placement Agents, which was entered into on June 3, 2026 (the "Placement Agreement").
Lock-up and undertakings
The Company has entered into a lock-up undertaking for a period of 90 days following the date of the settlement and delivery of the Offering, subject to certain customary exceptions.
The members of the Company’s Board of Directors and Executive Committee, including the Chief Executive Officer, have undertaken to retain the Company’s shares that they hold for a period of 90 days from the settlement-delivery date of the Offering, subject to certain customary exceptions. Lion Point Capital has also undertaken not to dispose of the shares it holds for a period of 90 days as from the settlement-delivery date of the Offering, subject to certain customary exceptions.
Eligibility of the Offering for PEA / PEA-PME schemes and the regime under Article 150-0 B ter of the French Tax Code, CGI, relating to the reinvestment of capital gains
Shares of Median Technologies are fully eligible for inclusion in share savings plans, or PEA, and PEA-PME accounts, which benefit from the same tax advantages as the standard PEA.
In the event of a contribution of securities to a company controlled by the contributor, the capital gain is placed under tax deferral pursuant to Article 150-0 B ter of the French Tax Code. The sale, within three years, of the contributed securities results in the termination of this tax deferral, unless the Company undertakes to reinvest 60% of the proceeds from the sale in an economic activity within two years of the sale. The sale proceeds may notably be invested in the cash subscription to the initial share capital or to a capital increase of one or more companies that meet the conditions provided for in Article 150-0 B ter of the French Tax Code. In this respect, the Offering constitutes an eligible reinvestment for maintaining the deferral of the capital gain on the contribution, with respect to the nature of the reinvestment.
The other conditions for application of the regime that are independent of the Company, including the reinvestment period and threshold, the holding of the new securities, and other applicable requirements, must also be complied with by the subscriber. Investors who may be eligible for this regime are invited to consult their usual tax adviser in order to assess their personal situation in light of the specific applicable regulations.
Risk factors
The main risk factors relating specifically to the Offering are set out below:
Shareholders not participating in the Offering will see their shareholding in the Company diluted by the issuance of the New Shares, and would see their shareholding diluted by any future capital increases made necessary by the Company’s ongoing openness to fundraising;
The market price of the Company’s shares may fluctuate and fall below the subscription price of the New Shares;
The volatility and liquidity of the Company’s shares may fluctuate significantly;
The other risk factors relating to the Company and its activities set out in the section "P Specific risk factors" of its 2025 annual financial report and of the information document, available on the Company’s website.
(Press release, MEDIAN Technologies, JUN 3, 2026, View Source [SID1234666421])